Stago Group News

Stago Accelerates Its Growth with ARCHIMED and La Caisse

Communication of April 29, 2026

For nearly eighty years, Stago has been developing solutions grounded in rigorous scientific standards, driven by a constant ambition: to support healthcare professionals and contribute to improved patient care.

As a leading global player in hemostasis, the company has built its identity on a culture of excellence, recognized expertise, and a long-term vision.

Today, Stago is entering a new phase in its history.

Stago webinar: Disseminated intravascular coagulation (DIC) - An in-depth look for 2026

Clinicians, clinical pathologists, researchers, and clinical laboratory staff will have the opportunity to deepen their knowledge of the pathophysiology of Disseminated intravascular coagulation (DIC) and the newly published ISTH definition and scoring system.

Stago at WHX Labs Dubai 2026: Four days of innovation and networking

Stago teams from Saudi Arabia, Turkey, Dubai, and headquarters participated in WHX Labs Dubai 2026, formerly known as Medlab Middle East. Held at the Dubai World Trade Centre, the event brought together over 35,000 professionals from 180 countries.

Communication of March 4, 2026

Dear valued Partner,
We are pleased to share an important update regarding Stago's future.

Stago has entered into an exclusive negotiations with ARCHIMED, a healthcare-focused investment firm and La Caisse, also active in the healthcare sector, to support the next phase of our growth.

This step reflects a strategic decision to further strengthen Stago's long-term growth while preserving what has always defined us: scientific excellence, reliability, deep expertise in hemostasis, and a strong commitment to customer partnerships.

Stago webinar: Emerging biomarker for thrombotic risk stratification in coronary artery disease

Clinicians, clinical pathologists, researchers, and clinical laboratory staff will have the opportunity to deepen their knowledge of the role of TF-positive platelets in arterial thrombosis and CAD progression, as well as their potential to improve thrombotic risk stratification beyond traditional models.